Početna › Mijelodisplastični sindromi › Massachusetts
Kliničke studije za Mijelodisplastični sindromi u državi Massachusetts
21 studija za Mijelodisplastični sindromi traži sudionike na lokacijama u državi Massachusetts.
Gradovi u državi Massachusetts
Službeni tekst studije (engleski)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06577441Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06484062MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- i još 1
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05564390Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT03471260Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT06465953The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
Do 22 godina · Oba spola · Ažurirano 25. kol 2026. · NCT04726241A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Brigham and Women's Hospital, Boston
U tijeku regrutacijaFaza 1Zdravi dobrovoljci dobrodošli
Od 18 do 75 godina · Oba spola · Ažurirano 28. srp 2026. · NCT07020533A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 12 godina i više · Oba spola · Ažurirano 17. lip 2026. · NCT04024761Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 17. lip 2026. · NCT06138587SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 17. lip 2026. · NCT03113643Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Dana-Farber Cancer Institute, Boston
- Dana Farber Cancer Institute at St. Elizabeth's, Brighton
- Dana Farber Cancer Institute at Merrimack Valley, Methuen
- i još 2
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 7. svi 2026. · NCT02269592A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 2/3
Od 18 godina i više · Oba spola · Ažurirano 30. tra 2026. · NCT04256317A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 24. ožu 2026. · NCT04988555Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 1 do 40 godina · Oba spola · Ažurirano 12. ožu 2026. · NCT05292664CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- DFCI/BWH Brigham and Women's Hospital, Boston
U tijeku regrutacijaFaza 2Zdravi dobrovoljci dobrodošli
Od 18 do 75 godina · Oba spola · Ažurirano 10. ožu 2026. · NCT06059391SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 28. lis 2025. · NCT03452774IS-free Treg HaploHCT
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 do 75 godina · Oba spola · Ažurirano 20. lis 2025. · NCT04678401HEME Home Transfusion Program
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 17. ruj 2025. · NCT06487247Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform
- Shwachman-Diamond Syndrome Alliance Inc., Woburn
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 31. svi 2025. · NCT06999954Study of REM-422 in Patients With AML or Higher Risk MDS
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 23. tra 2025. · NCT06297941Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 15. tra 2025. · NCT06462365Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.